Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
phones are quite cheap..
sure Dr Kim confident always..
Updates from Rodman & renshaw Conference
Joseph speaks at length during the conf...
http://www.earningsimpact.com/Transcript/83546/INO/15th-Annual-Rodman-and-Renshaw-Global-Investment-Conference
Sure.. info sharing has to be there.. market should not react just based on sentiments..
More on INO-1800's potential to treat hepatitis C infection & stop progression of infection into liver cancer, updates given at investor conf call.
details here
http://www.earningsimpact.com/Transcript/83553/INO/Conference-Call-to-Discuss-Partnership-with-Roche
Expect to initiate the first INO-8000 clinical trial by the end of this year
what are the chances Yahoo buying blackbry?
Updates from Rodman & Renshaw Conference presentation
Leo (CEO) discusses various phases of Cellceutix.. insightful..
http://www.earningsimpact.com/Transcript/83510/CTIX/15th-Annual-Rodman-and-Renshaw-Global-Investment-Conference
Entry point?
Peregrine expects contract manufacturing revenue for the entire fiscal year '14 to be between $18 million and $22 million
http://www.earningsimpact.com/Transcript/83462/PPHM/Q1-2014-Earnings-Call
Transcript of Investor Conference about partnership
Roche and Inovio have entered into an exclusive worldwide licensing and collaboration agreement to develop and commercialize Inovio's DNA immunotherapies targeting prostate cancer and hepatitis C
partnership with Roche is for three clinical products
http://www.earningsimpact.com/Transcript/83553/INO/Inovio-Pharmaceuticals%2c-Inc----Conference-Call-to-Discuss-Partnership-with-Roche
yeah could be largest
Good time for entry?
R&D expense increased $224,000 from $211,000 in Q2 of 2012
Good sign?
http://www.earningsimpact.com/Transcript/83483/LQMT/Liquidmetal-Technologies%2c-Inc---Q2-2013-Earnings-Call
Article on Fannie mae.. Have steps taken by the Federal Reserve helped the economy pick up steam
http://www.earningsimpact.com/Ideaz.aspx
thanks for the link.. good read
Presenting today at Rodman conf at 11.15... looking forward to it
Facebook users & other stats here
Facebook has about 240 billion photos aggregated so far... thats amazing....
http://www.earningsimpact.com/Ideaz.aspx
CEO Matthew Lehman on Prima Biomed's cancer therapuetics @ The 15th Annual Rodman & Renshaw Conference
http://www.earningsimpact.com/Transcript/83507/PBMD/15th-Annual-Rodman-and-Renshaw-Global-Investment-Conference
good entry here
yeah right.. hope so
Updates from Conference transcript
The Phase 3 is named SUNRISE an acronym which stands for stimulating immune response through bavituximab in a Phase 3 lung cancer study.
Ended the quarter with $41.6 million in cash compared to $35.2 million in cash at fiscal year end April 30, 2013
http://www.earningsimpact.com/Transcript/83462/PPHM/Q1-2014-Earnings-Call
CEO discusses IPO of semiconductor business during just held conference call.
http://www.earningsimpact.com/Transcript/83339/SUNE/Business-Update-Call
BiotechWatchlist today Sept 9 PPHM RXII INO ISIS
Nice comparison of NOK with BBRY on where the latter could be headed next
where does blackberry stand?
http://www.earningsimpact.com/Ideaz.aspx
Interesting article on vringo
What’s Next for Vringo Post-Ruling in Litigation.
http://www.earningsimpact.com/Ideaz/9/What%e2%80%99s-Next-for-Vringo-Post-Ruling-in-Litigation-Against-AOL%2c-Google-and-Others
reverse split?
looking forward to rodman conference.. hoping for some good updates
Tom's remarks during conf call
Tom (CEO) feels that cash reserves are sufficient to through the first quarter of 2014 and are being cautious with cash expenditures while being as aggressive as possible about turning prototypes into production, of all machine technology to the next level and pursuing license and alternatives where ever possible.
http://www.earningsimpact.com/Transcript/83483/LQMT/Liquidmetal-Technologies%2c-Inc---Q2-2013-Earnings-Call
conf call today at 4.30pm
presentation at Rodman should be interesting..
Details during earnings conf call
Litigation expenses in second quarter was somewhat lower than first quarter.
Also since the start of 2012 thay have acquired almost 1000 patents and patent applications in key spaces.
http://www.earningsimpact.com/Transcript/83480/IDCC/InterDigital%2c-Inc----Q2-2013-Earnings-Call
Half way through 2013, development expenses in total are 30 million in line with that guided range
Pleasure.. haha happy hour
Where will it go next week?
Insightful presentation at 2013 Stephens Spring Investment Conference
William J. Merritt, President and Chief Executive Officer discusses various business aspects.
http://www.earningsimpact.com/Transcript/82062/IDCC/InterDigital%2c-Inc----2013-Stephens-Spring-Investment-Conference
Updates during conf call.. Otsuka Pharmaceutical Company Limited's agreement to acquire Astex Pharmaceuticals Incorporated for $8.50 per fully diluted share in cash for total consideration of approximately $886 million calculated using the Treasury Stock Method.
http://www.earningsimpact.com/Transcript/83446/ASTX/Astex-Pharmaceuticals%2c-Inc----Otsuka-Pharmaceutical-to-Acquire-Astex-Pharmaceuticals
Product sales for the third quarter totaled 45.4 million compared to 21 million reported in the prior year
Revenue from product shipments and EPC services at the Bridgeport fuel cell park was the primary driver for the year-over-year revenue
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91744979
FCEL earnings call updates
The company owns approximately 46,000 megawatts of power generation and service over 2 million retail customers
http://www.earningsimpact.com/Transcript/83444/FCEL/FuelCell-Energy%2c-Inc----Q3-2013-Earnings-Call
CEO states that "MiMedx has many of the concerns about the development of the Amniotic Membrane Allograft products as does the FDA." during conf call
http://www.earningsimpact.com/Transcript/83438/MDXG/MiMedx-Group-Inc---Business-Update-Call